HealthDay News — For patients with chronic obstructive pulmonary disease (COPD), once-daily single-inhaler triple therapy is better for lung function and health-related quality of life than inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA) therapy, according to a study published in the American Journal of Respiratory and Critical Care Medicine.

David A. Lipson, MD, from GlaxoSmithKline in King of Prussia, PA, and colleagues compared the effects of once-daily triple therapy on lung function and health-related quality of life with twice-daily ICS/LABA therapy for 24 weeks as part of a randomized trial. A total of 1810 participants were randomized to triple therapy (911 patients; fluticasone furoate/umeclidinium/vilanterol) and ICS/LABA therapy (899 patients; budesonide/formoterol). A subgroup of patients remained on blinded treatment for up to 52 weeks.

The researchers found that the mean changes from baseline in forced expiratory volume in 1 (FEV1) second were 142 mL and -29 mL, for the triple therapy and ICS/LABA therapy groups, respectively; mean changes from baseline in St. George’s Respiratory Questionnaire scores were -6.6 and -4.3 units, respectively. The between-group differences for both end points were statistically significant. For triple therapy versus dual ICS/LABA therapy there was a statistically significant reduction in moderate/severe exacerbation rates (35% reduction).

Continue Reading

“These results support the benefits of single-inhaler triple therapy compared with ICS/LABA therapy in patients with advanced COPD,” the authors write.

Disclosures: Several authors disclosed financial ties to GlaxoSmithKline, which funded the study.

Related Articles


Lipson DA, Barnacle H, Birk R, et al. FULFIL Trial: Once-daily triple therapy for patients with chronic obstructive pulmonary disease [published online August 15, 2017]. Am J Resp Crit Care Med. doi:10.1164/rccm.201703-0449OC